Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.80 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376516 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL18784962 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104629 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| SCHEMBL376515 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL10044131 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL104630 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL105273 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL15810768 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL21311175 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 | |
| Cystetine Triphosphate SCHEMBL4289439 | 1.00 | P2RY2 (0.80) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | claimed |
| WO-2025060527-A1 | 3'-SIALYLLACTOSE-PRODUCING ENGINEERED BACTERIUM, AND CONSTRUCTION METHOD AND APPLICATION THEREOF | SYNAURA BIOTECHNOLOGY (SHANGHAI) CO., LTD. (CN) | 2025-03-27 | — | — | WO | claimed |
| US-20240368655-A1 | CLICK HANDLE-MODIFIED DEOXY-FLUOROARABINO NUCLEIC ACID AS A SYNTHETIC GENETIC POLYMER CAPABLE OF POST-POLYMERIZATION FUNCTIONALIZATION | NATIONAL INSTITUTES OF HEALTH | 2024-11-07 | — | — | US | claimed |
| US-20240226335-A9 | RNA Containing Modified Nucleosides and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-07-11 | — | — | US | claimed |
| US-20240131194-A1 | RNA Containing Modified Nucleosides and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2024-04-25 | — | — | US | claimed |
| CN-115060823-B | Method for separating nucleoside triphosphates and/or deoxynucleoside triphosphates by HPLC | 生工生物工程（上海）股份有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-115060823-A | Method for separating nucleoside triphosphates and/or deoxynucleoside triphosphates by HPLC | 生工生物工程（上海）股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-11389547-B2 | RNA containing modified nucleosides and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-07-19 | — | — | US | claimed |
| US-11246965-B2 | Compositions and methods for reducing neointima formation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-02-15 | — | — | US | claimed |
| CN-111635532-B | Aggregation-induced fluorescence guest functionalized composite infinite coordination polymer nanoparticle and preparation and application thereof | 华东师范大学 | 2021-07-27 | — | — | CN | claimed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| EP-1025115-B1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INT (FR) | 2003-06-04 | — | — | EP | claimed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | claimed |
| EP-0897301-B1 | METHOD OF TREATING OTITIS MEDIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS INC (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| EP-1025115-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INTERNATIONAL (FR) | 2000-08-09 | — | — | EP | claimed |
| WO-1999018114-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INTERNATIONAL (FR) | 1999-04-15 | — | — | WO | claimed |
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | claimed |
| US-RE28886-E | Method for preparing cytidine diphosphate choline | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246965-B2 | Compositions and methods for reducing neointima formation | CTPS1, CTPS2, TNNI3 | P2RY2 1867/4885P2RY6 1518/4885P2RY4 1902/4885 |
| US-20240368655-A1 | CLICK HANDLE-MODIFIED DEOXY-FLUOROARABINO NUCLEIC ACID AS A SYNTHETIC GENETIC POLYMER CAPABLE OF POST-POLYMERIZATION FUNCTIONALIZATION | RNGTT, UNG, DCTD | P2RY2 1794/4885P2RY6 1163/4885P2RY4 991/4885 |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | P2RY1, P2RY2, P2RY6 | P2RY2 2/4885P2RY6 3/4885P2RY4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.